ATE175575T1 - Arzneimittel zur behandlung von osteoporose - Google Patents

Arzneimittel zur behandlung von osteoporose

Info

Publication number: ATE175575T1
Authority: AT; Austria
Prior art keywords: compounds; osteoporosis; isoadhumulone; isocohumulone; adhumulone
Prior art date: 1994-04-12

Application number

AT95105177T

Other languages

English (en)

Inventor

Hiroyasu Tobe

Kazuyuki Kitamura

Original Assignee

Hoechst Marion Roussel Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-12

Filing date

1995-04-06

Publication date

1999-01-15

1995-04-06 Application filed by Hoechst Marion Roussel Ltd filed Critical Hoechst Marion Roussel Ltd

1999-01-15 Application granted granted Critical

1999-01-15 Publication of ATE175575T1 publication Critical patent/ATE175575T1/de

Links

208000001132 Osteoporosis Diseases 0.000 title abstract 3
229940126601 medicinal product Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
QARXXMMQVDCYGZ-UHFFFAOYSA-N isohumulone Chemical compound CC(C)CC(=O)C1=C(O)C(O)(C(=O)CC=C(C)C)C(CC=C(C)C)C1=O QARXXMMQVDCYGZ-UHFFFAOYSA-N 0.000 abstract 4
LDXMPKMQIKGJFN-OKKPIIHCSA-N (6r)-3,5,6-trihydroxy-2-(2-methylbutanoyl)-4,6-bis(3-methylbut-2-enyl)cyclohexa-2,4-dien-1-one Chemical compound CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@](O)(CC=C(C)C)C1=O LDXMPKMQIKGJFN-OKKPIIHCSA-N 0.000 abstract 2
QHRQNLXYMFCGPB-UHFFFAOYSA-N 3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbut-2-enyl)-4-(4-methylpent-3-enoyl)cyclopent-2-en-1-one Chemical compound CCC(C)C(=O)C1=C(O)C(O)(C(=O)CC=C(C)C)C(CC=C(C)C)C1=O QHRQNLXYMFCGPB-UHFFFAOYSA-N 0.000 abstract 2
KKXFYHZSOIALRM-UHFFFAOYSA-N 3,4-dihydroxy-5-(3-methylbut-2-enyl)-4-(4-methylpent-3-enoyl)-2-(2-methylpropanoyl)cyclopent-2-en-1-one Chemical compound CC(C)C(=O)C1=C(O)C(O)(C(=O)CC=C(C)C)C(CC=C(C)C)C1=O KKXFYHZSOIALRM-UHFFFAOYSA-N 0.000 abstract 2
LDXMPKMQIKGJFN-SPLOXXLWSA-N Adhumulone Natural products O=C([C@@H](CC)C)C=1C(=O)[C@@](O)(C/C=C(\C)/C)C(O)=C(C/C=C(\C)/C)C=1O LDXMPKMQIKGJFN-SPLOXXLWSA-N 0.000 abstract 2
DRSITEVYZGOOQG-UHFFFAOYSA-N Cohumulone Chemical compound CC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O DRSITEVYZGOOQG-UHFFFAOYSA-N 0.000 abstract 2
DRSITEVYZGOOQG-HXUWFJFHSA-N Cohumulone Natural products CC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@](O)(CC=C(C)C)C1=O DRSITEVYZGOOQG-HXUWFJFHSA-N 0.000 abstract 2
RMFGNMMNUZWCRZ-UHFFFAOYSA-N Humulone Natural products CC(C)CC(=O)C1=C(O)C(O)(CC=C(C)C)C(O)=C(CC=C(C)C)C1=O RMFGNMMNUZWCRZ-UHFFFAOYSA-N 0.000 abstract 2
229930193815 Isohumulone Natural products 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 2
150000007513 acids Chemical class 0.000 abstract 2
VMSLCPKYRPDHLN-NRFANRHFSA-N humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@@](O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-NRFANRHFSA-N 0.000 abstract 2
VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical class CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 abstract 1
208000006386 Bone Resorption Diseases 0.000 abstract 1
235000008694 Humulus lupulus Nutrition 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000024279 bone resorption Effects 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000004615 ingredient Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Natural Medicines & Medicinal Plants (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Orthopedic Medicine & Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Medical Informatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Botany (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

AT95105177T 1994-04-12 1995-04-06 Arzneimittel zur behandlung von osteoporose ATE175575T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP7323094		1994-04-12

Publications (1)

Publication Number	Publication Date
ATE175575T1 true ATE175575T1 (de)	1999-01-15

Family

ID=13512179

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95105177T ATE175575T1 (de)	1994-04-12	1995-04-06	Arzneimittel zur behandlung von osteoporose

Country Status (13)

Country	Link
US (1)	US5604263A (de)
EP (1)	EP0677289B1 (de)
KR (1)	KR950031059A (de)
AT (1)	ATE175575T1 (de)
AU (1)	AU696334B2 (de)
CA (1)	CA2146820A1 (de)
DE (1)	DE69507185T2 (de)
DK (1)	DK0677289T3 (de)
ES (1)	ES2129691T3 (de)
FI (1)	FI951702L (de)
HU (1)	HUT71604A (de)
NO (1)	NO951422L (de)
TW (1)	TW427901B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7666449B2 (en) *	2001-06-20	2010-02-23	Metaproteomics, Llc	Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US8142819B2 (en) *	2002-10-21	2012-03-27	Metaproteomics, Llc	Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US8168234B2 (en)	2001-06-20	2012-05-01	Metaproteomics, Llc	Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8206753B2 (en) *	2001-06-20	2012-06-26	Metaproteomics, Llc	Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7718198B2 (en) *	2001-06-20	2010-05-18	Metaproteomics, Llc	Treatment modalities for autoimmune diseases
US20040219240A1 (en) *	2001-06-20	2004-11-04	Babish John G.	Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7901714B2 (en) *	2001-06-20	2011-03-08	Metaproteomics, Llp	Treatment modalities for autoimmune diseases
US20040115290A1 (en) *	2001-06-20	2004-06-17	Tripp Matthew L.	Modulation of inflammation by hops fractions and derivatives
US7270835B2 (en) *	2001-06-20	2007-09-18	Metaproteomics, Llc	Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) *	2001-06-20	2007-04-17	Metaproteomics, Llc	Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7901713B2 (en) *	2001-06-20	2011-03-08	Metaproteomics, Llc	Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US20090263522A1 (en) *	2001-10-26	2009-10-22	Babish John G	Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2
US7279185B2 (en) *	2001-10-26	2007-10-09	Metaproteonics, Llc	Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US8158160B2 (en)	2001-11-13	2012-04-17	Eric Hauser Kuhrts	Anti-inflammatory cyclooxygenase inhibitors
KR100993113B1 (ko) *	2002-02-14	2010-11-08	기린 홀딩스 가부시키가이샤	지질대사 개선용 조성물 및 식품
MXPA05004288A (es) *	2002-10-21	2005-08-02	Metaproteomics Llc	Composiciones para tratar o inhibir los estados patologicos asociados con la respuesta inflamatoria.
JP2005104951A (ja) *	2003-01-17	2005-04-21	Kirin Brewery Co Ltd	血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
NZ543726A (en) *	2003-05-22	2009-08-28	Metaproteomics Llc	Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US20050192356A1 (en) *	2004-02-27	2005-09-01	Babish John G.	Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7914831B2 (en) *	2004-02-27	2011-03-29	Metaproteomics, Llc	Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
CA2618613A1 (en) *	2005-08-09	2007-02-22	Metaproteomics, Llc	Protein kinase modulation by hops and acacia products
AU2006321727A1 (en) *	2005-12-09	2007-06-14	Metaproteomics, Llc	Protein kinase modulation by hops and Acacia products
US20080031982A1 (en) *	2006-06-20	2008-02-07	Metaproteomics, Llc	Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
US20080051466A1 (en) *	2006-06-20	2008-02-28	Metaproteomics, Llc	Isoalpha acid based protein kinase modulation cancer treatment
NZ579340A (en) *	2007-03-19	2012-05-25	Metaproteomics Llc	Methods and compositions for promoting bone and joint health comprising berberine
WO2008140842A1 (en)	2007-05-11	2008-11-20	Metaproteomics, Llc	Methods and compositions for heavy metal detoxification
JP2011506464A (ja) *	2007-12-10	2011-03-03	メタプロテオミクス，エルエルシー	癌、血管新生及びそれらに関連する炎症経路の置換１，３−シクロペンタジオン多重標的プロテインキナーゼ・モジュレーター
EP2268600A4 (de) *	2008-04-02	2012-03-21	Metaproteomics Llc	Substituierte 1,3-cyclopentadion-gedämpfte endothelialentzündungs- und endothelial-monocyteninteraktionen
EP3752172A4 (de) *	2018-02-16	2021-12-01	The New Zealand Institute For Plant And Food Research Limited	Orale darreichungsformen mit einem hopfenextrakt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3892808A (en) *	1965-11-17	1975-07-01	Carlton & United Breweries	Hop extracts
DE1901277A1 (de) *	1969-01-10	1970-08-06	Partipharm Ag	Mittel zur Kompensation uebermaessigen Zigarettenkonsums
US5370863A (en) *	1992-12-16	1994-12-06	Miller Brewing Company	Oral care compositions containing hop acids and method
JPH06312924A (ja) *	1993-04-28	1994-11-08	Asahi Breweries Ltd	抗酸化作用を有するフムロン類の利用

1995
- 1995-04-06 DK DK95105177T patent/DK0677289T3/da active
- 1995-04-06 DE DE69507185T patent/DE69507185T2/de not_active Expired - Fee Related
- 1995-04-06 ES ES95105177T patent/ES2129691T3/es not_active Expired - Lifetime
- 1995-04-06 EP EP95105177A patent/EP0677289B1/de not_active Expired - Lifetime
- 1995-04-06 AT AT95105177T patent/ATE175575T1/de not_active IP Right Cessation
- 1995-04-10 FI FI951702A patent/FI951702L/fi unknown
- 1995-04-10 US US08/420,728 patent/US5604263A/en not_active Expired - Fee Related
- 1995-04-11 AU AU16384/95A patent/AU696334B2/en not_active Ceased
- 1995-04-11 HU HU9501043A patent/HUT71604A/hu unknown
- 1995-04-11 NO NO951422A patent/NO951422L/no not_active Application Discontinuation
- 1995-04-11 CA CA002146820A patent/CA2146820A1/en not_active Abandoned
- 1995-04-11 KR KR1019950008333A patent/KR950031059A/ko not_active Withdrawn
- 1995-05-05 TW TW084104477A patent/TW427901B/zh active

Also Published As

Publication number	Publication date
FI951702A7 (fi)	1995-10-13
CA2146820A1 (en)	1995-10-13
AU696334B2 (en)	1998-09-10
KR950031059A (ko)	1995-12-18
NO951422D0 (no)	1995-04-11
AU1638495A (en)	1995-10-19
EP0677289A3 (de)	1996-10-23
DE69507185T2 (de)	1999-09-09
EP0677289B1 (de)	1999-01-13
HU9501043D0 (en)	1995-06-28
ES2129691T3 (es)	1999-06-16
DE69507185D1 (de)	1999-02-25
HUT71604A (en)	1996-01-29
FI951702A0 (fi)	1995-04-10
NO951422L (no)	1995-10-13
US5604263A (en)	1997-02-18
EP0677289A2 (de)	1995-10-18
FI951702L (fi)	1995-10-13
DK0677289T3 (da)	1999-09-06
TW427901B (en)	2001-04-01

Legal Events

Date	Code	Title	Description
2000-04-15	UEP	Publication of translation of european patent specification
2001-01-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE175575T1 (de)	1999-01-15	Arzneimittel zur behandlung von osteoporose
ATE162073T1 (de)	1998-01-15	Pharmazeutische zusammensetzung zur behandlung von osteoporose enthaltend xanthohumol
DK0750618T3 (da)	2003-06-10	Oxazolidinonderivater og farmaceutiske præparater indeholdende dem
ATE205086T1 (de)	2001-09-15	Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ATE146677T1 (de)	1997-01-15	Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
DE60022683D1 (de)	2005-10-20	Nervenschutzmittel
ATE439833T1 (de)	2009-09-15	Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
HUP9603489A2 (hu)	1998-08-28	Gyógyszerkészítmény és eljárás előállítására
UY26514A1 (es)	2001-07-31	" composición para el tratamiento de tejidos danados".
AP9901474A0 (en)	1999-03-31	Pharmaceutical composition for treating viral diseases.
ATE263566T1 (de)	2004-04-15	Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
DE68916651D1 (de)	1994-08-11	Heilmittel zur behandlung von toxoplasmose.
EP0820771A3 (de)	2001-03-07	Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält
UA41326C2 (uk)	2001-09-17	Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
MC2203A1 (fr)	1992-11-26	Medicament contre la cryptosporidiose
DE60113895D1 (de)	2006-02-23	Verwendung von Tiludronsäure beim Geflügel zur Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von Osteoporose
US20050020693A1 (en)	2005-01-27	Pharmaceutical preparations useful as drying agents and for treatment of warts
DE60028682D1 (de)	2006-07-27	Wachstumhormone Inhibitoren Enthaltende pharmazeutische Zubereitungen oder ihre biologisch aktive Fragmente zur Behandlung von uterinen Myomas
TH45859A3 (th)	2001-06-22	แอซิลกวานิดีนซึ่งถูกแทนที่ด้วยไธเอนิลในฐานะเป็นตัวยับยั้งการขจัดเอาเนื้อเยื่อกระดูกออกและเป็นแอนทากอนิสท์ของตัวรับไวโทรเน็คทิน